SPNT Stock Analysis: Siriuspoint | NYSE
Insurance - Reinsurance | NYSE, USA | Market Cap: 2.809m USD | 12M Return: 29.9% | BMG8192H1060 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 12.8M
EPS Trend: 42.1%
Qual. Beats: 0
Rev. Trend: 74.6%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
SiriusPoint Ltd. is a global multi-line reinsurance and insurance company headquartered in Pembroke, Bermuda, operating through four main segments: Global P&C Programs, Global Reinsurance, Global Accident & Health, and London Market Specialty. Its offerings span casualty, property, aviation and space, marine and energy, credit, surety, and mortgage risks, serving insurance companies, government entities, and other risk-bearing vehicles. The Global Accident & Health segment also provides specialty consumer products such as travel medical insurance, trip cancellation programs, and 24/7 emergency assistance services. The company was originally incorporated in 2011 as Third Point Reinsurance Ltd. and rebranded to SiriusPoint Ltd. in February 2021.
As a Bermuda-domiciled reinsurer, SiriusPoint operates from one of the worlds leading insurance and reinsurance hubs, a jurisdiction that has historically attracted specialty insurers due to its favorable regulatory and tax environment. Reinsurance carriers like SiriusPoint function as a financial buffer for primary insurers, helping them manage catastrophic and large-loss exposures by spreading risk across global capital pools.
- Catastrophe losses pressure Global Reinsurance combined ratio
- Reinsurance pricing hardens at mid-year renewals boosting premium rates
- Investment income surges on higher yields from float portfolio
- Share buyback program accelerates as excess capital returns to shareholders
| Net Income: 505.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.80 > 1.0 |
| NWC/Revenue: -26.93% < 20% (prev -49.82%; Δ 22.90% < -1%) |
| CFO/TA 0.02 > 3% & CFO 243.2m > Net Income 505.6m |
| Net Debt (-5.20b) to EBITDA (683.1m): -7.62 < 3 |
| Current Ratio: 0.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (119.0m) vs 12m ago -26.25% < -2% |
| Gross Margin: 50.52% > 18% (prev 25.02%; Δ 25.50% > 0.5%) |
| Asset Turnover: 25.96% > 50% (prev 21.41%; Δ 4.55% > 0%) |
| Interest Coverage Ratio: 8.85 > 6 (EBIT TTM 672.9m / Interest Expense TTM 76.0m) |
| A: -0.07 (Total Current Assets 8.55b - Total Current Liabilities 9.43b) / Total Assets 12.7b |
| B: 0.11 (Retained Earnings 1.40b / Total Assets 12.7b) |
| C: 0.05 (EBIT TTM 672.9m / Avg Total Assets 12.5b) |
| D: 0.22 (Book Value of Equity 2.28b / Total Liabilities 10.4b) |
| Altman-Z'' = 0.50 = B |
As of September 05, 2026, the stock is trading at USD 24.48 with a total of 811,347 shares traded. Over the past week, the price has changed by +1.24%, over one month by +2.30%, over three months by +16.41% and over the past year by +29.87%.
Current recommended Stop Loss: 23.50 (which is 4% or 1.8 ATR below the current price).
Siriuspoint has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold SPNT.
- StrongBuy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 27.7 | 13% |
P/E Trailing = 5.9265
P/E Forward = 9.6712
P/S = 0.9361
P/B = 1.2286
Revenue TTM = 3.25b USD
EBIT TTM = 672.9m USD
EBITDA TTM = 683.1m USD
Long Term Debt = 675.5m USD (from longTermDebt, last quarter)
Short Term Debt = 3.50m USD (from shortTermDebt, last quarter)
Debt = 700.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -5.20b USD (calculated: Debt 700.9m - CCE 5.90b)
Enterprise Value = 2.81b USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = 8.85 (Ebit TTM 672.9m / Interest Expense TTM 76.0m)
EV/FCF = 11.55x (Enterprise Value 2.81b / FCF TTM 243.2m)
FCF Yield = 8.66% (FCF TTM 243.2m / Enterprise Value 2.81b)
FCF Margin = 7.49% (FCF TTM 243.2m / Revenue TTM 3.25b)
Net Margin = 15.58% (Net Income TTM 505.6m / Revenue TTM 3.25b)
Gross Margin = 50.52% ((Revenue TTM 3.25b - Cost of Revenue TTM 1.61b) / Revenue TTM)
Gross Margin QoQ = 51.86% (prev 53.15%)
Tobins Q-Ratio = 0.22 (Enterprise Value 2.81b / Total Assets 12.7b)
Interest Expense / Debt = 10.84% (Interest Expense 76.0m / Debt 700.9m)
Taxrate = 15.30% (91.3m / 596.9m)
NOPAT = 570.0m (EBIT 672.9m * (1 - 15.30%))
Current Ratio = 0.91 (Total Current Assets 8.55b / Total Current Liabilities 9.43b)
Debt / Equity = 0.31 (Debt 700.9m / totalStockholderEquity, last quarter 2.28b)
Debt / EBITDA = -7.62 (Net Debt -5.20b / EBITDA 683.1m)
Debt / FCF = -21.39 (Net Debt -5.20b / FCF TTM 243.2m)
Total Stockholder Equity = 2.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.04% (Net Income 505.6m / Total Assets 12.7b)
RoE = 21.84% (Net Income TTM 505.6m / Total Stockholder Equity 2.31b)
RoCE = 22.51% (EBIT 672.9m / Capital Employed (Equity 2.31b + L.T.Debt 675.5m))
RoIC = 18.60% (NOPAT 570.0m / Invested Capital 3.07b)
WACC = 5.97% (E(2.81b)/V(3.51b) * Re(5.17%) + D(700.9m)/V(3.51b) * Rd(10.84%) * (1-Tc(0.15)))
Discount Rate = 5.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.14 | Cagr: -15.62%
[DCF] Terminal Value 77.97% ; FCFF base≈201.5m ; Y1≈231.0m ; Y5≈340.0m
[DCF] Fair Price = 88.82 (EV 5.12b - Net Debt -5.20b = Equity 10.3b / Shares 116.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 42.14 | EPS CAGR: 19.89% | SUE: 0.08 | # QB: 0
Revenue Correlation: 74.62 | Revenue CAGR: 7.26% | SUE: -0.04 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.58 | Chg30d=-1.28% | Revisions=-17% | Analysts=4
EPS current Year (2026-12-31): EPS=2.60 | Chg30d=+1.46% | Revisions=+40% | GrowthEPS=+2.2% | GrowthRev=-3.5%
EPS next Year (2027-12-31): EPS=2.76 | Chg30d=-0.18% | Revisions=+17% | GrowthEPS=+5.9% | GrowthRev=+5.5%
[Analyst] Revisions Ratio: +18% (up=5, down=3)